Endoscopic ultrasound-guided fine-needle aspiration for suspected malignancies adjacent to the gastrointestinal tract

Table 3 Accuracy and efficiency and quality assessment n (%)

	MRS1 (n = 312)	MRS2 (n = 276)	MRS3 (n = 431)	Overall (n = 1019)
AC: (TP+TN)/N	0.97	0.87	1	0.95
ST: TP/N (D+)	0.85	0.79	0.99	0.93
SP: TP/N (D-)	1	1	1	1
PPV: TP/N (T+)	1	1	1	1
NPV: TN/N (T-)	0.97	0.76	0.95	0.90
+LR (ST/1-SP)	0	0	0	0
-LR (SP/1-ST)	6.6	4.7	100	4.2
TP	36 (3.5)	109 (10.6)	370 (36)	616 (60.4)
TN	231 (22.6)	101 (9.9)	26 (2.5)	403 (39.5)
IT	39 (12.5)	55 (19.9)	35 (8.1)	129 (12.6)
TDCD mean days (range)	25.4 (8-32)c	16.2 (11-24)a	12.4 (10-21)a	16.3 (8-32)
Patients TP treated with surgery or CRT	36 (3.5)c	109 (10.7)a	370 (36.3)a	515 (50.5)
Patients with inconclusive tests treated (surgery-CRT)	16 (9-7)	21 (12-9)	18 (13-5)	55 (34-21)

Calculation of accuracy (AC), sensitivity (ST), specificity (SP), and positive (PPV) and negative (NPV) predictive values for malignant risk score (MRS)-1, MRS-2 and MRS-3, likelihood ratios for positive and negative test (+LR, -LR) for different groups of patients. D+: Number of patients with positive final diagnosis; D-: Number of patients with negative final diagnosis; IT: Inconclusive test; TDCD: Time to definitive cytological diagnosis; CRT: Chemo-Radio-Therapy.

^aP < 0.05 vs MRS1;

^cP < 0.05 vs MRS3 according to the Scheffépost-hoc test.